JPH08165249A - Composition having bone strengthening action - Google Patents
Composition having bone strengthening actionInfo
- Publication number
- JPH08165249A JPH08165249A JP6333126A JP33312694A JPH08165249A JP H08165249 A JPH08165249 A JP H08165249A JP 6333126 A JP6333126 A JP 6333126A JP 33312694 A JP33312694 A JP 33312694A JP H08165249 A JPH08165249 A JP H08165249A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- derived
- basic protein
- calcium
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 210000000988 bone and bone Anatomy 0.000 title abstract description 37
- 238000005728 strengthening Methods 0.000 title abstract description 28
- 235000013336 milk Nutrition 0.000 claims abstract description 182
- 239000008267 milk Substances 0.000 claims abstract description 182
- 210000004080 milk Anatomy 0.000 claims abstract description 182
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 123
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 85
- 239000011575 calcium Substances 0.000 claims abstract description 85
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 85
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 239000007787 solid Substances 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 7
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003729 cation exchange resin Substances 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 7
- 235000006694 eating habits Nutrition 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 description 79
- 238000012360 testing method Methods 0.000 description 28
- 238000000034 method Methods 0.000 description 26
- 239000000843 powder Substances 0.000 description 23
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 235000013618 yogurt Nutrition 0.000 description 21
- 230000035622 drinking Effects 0.000 description 17
- 230000037118 bone strength Effects 0.000 description 16
- 235000013351 cheese Nutrition 0.000 description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 235000014059 processed cheese Nutrition 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 208000008924 Femoral Fractures Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 235000015140 cultured milk Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- -1 drinks Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000021243 milk fat Nutrition 0.000 description 5
- 208000020084 Bone disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 235000020185 raw untreated milk Nutrition 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940036811 bone meal Drugs 0.000 description 2
- 239000002374 bone meal Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- WQAQKERCWPUIMH-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CN1C(C)=CC(=O)N1C1=CC=CC=C1 WQAQKERCWPUIMH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015142 cultured sour cream Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、乳由来の塩基性タンパ
ク質および乳由来のカルシウムを含有し、骨強化作用を
有する組成物に関する。本発明における骨強化作用を有
する組成物は、経口投与製剤あるいは食品や飲料(以下
まとめて飲食品ということがある)の形態で用いら
れ、高齢者に多い骨粗鬆症患者や成長期の学童の骨強化
に有効である。FIELD OF THE INVENTION The present invention relates to a composition containing a milk-derived basic protein and milk-derived calcium and having a bone-reinforcing action. The composition having a bone-reinforcing action in the present invention is used in the form of an orally-administered preparation or a food or beverage (hereinafter, may be collectively referred to as a food or drink), and is used for bone-reinforcing in osteoporosis patients and growing school children, which are common in the elderly. Is effective for.
【0002】[0002]
【従来の技術】近年、高齢者に骨粗鬆症、骨折、腰痛等
の各種骨疾患患者が増加している。これは、カルシウム
の摂取不足、カルシウム吸収能力の低下、閉経後のホル
モンのアンバランス等が原因であるとされている。この
ように高齢者に多い骨粗鬆症や骨折などの各種骨疾患を
予防するためには、骨量をできるだけ増加させて最大骨
量(peak bone mass)を高めることが有効であるとされて
いる。そして、最大骨量を高めるということは、まさし
く骨を強化することに他ならない。上記したように、各
種骨疾患患者の増加傾向にある現状の中、骨強化を目的
として、炭酸カルシウム、リン酸カルシウム、乳酸カル
シウムなどのカルシウム塩や乳清カルシウム、牛骨粉、
卵殻などの天然カルシウム剤が、単独またはカゼインフ
ォスフォペプチド等のカルシウム吸収を促進すると考え
られている素材と共に食品に添加されている。2. Description of the Related Art In recent years, the number of patients with various bone diseases such as osteoporosis, bone fracture and low back pain has been increasing in the elderly. It is said that this is due to insufficient intake of calcium, decreased calcium absorption ability, imbalance of postmenopausal hormones, and the like. Thus, in order to prevent various bone diseases such as osteoporosis and bone fracture, which are common in the elderly, it is effective to increase the bone mass as much as possible to increase the peak bone mass. And increasing the maximum bone mass is nothing but strengthening the bone. As described above, in the current trend of increasing the number of patients with various bone diseases, for the purpose of bone strengthening, calcium carbonate, calcium phosphate, calcium salts such as calcium lactate and whey calcium, beef bone powder,
Natural calcium agents such as egg shells have been added to foods either alone or with materials thought to promote calcium absorption such as caseinphosphopeptides.
【0003】しかしながら、これらのカルシウムを他の
成分と共に食品として摂取した場合、その吸収率は50%
以下であり、半分以上が吸収されずに体外に排出されて
しまうと言われている。また、体内に吸収されたカルシ
ウムもその形態や、同時に摂取される他の栄養成分の種
類によって、骨への親和性が異なるので、骨代謝改善お
よび骨強化作用を示さないこともある。この他、骨粗鬆
症治療や骨強化のための医薬として、ビタミンD3 やカ
ルシトニン製剤などが知られているが、これらの医薬を
用いた場合、耳鳴り、頭痛、食欲不振などの副作用を伴
うことがあり、また、これらの医薬として用いられてい
る物質は、安全性および経済性等の面から現在のところ
飲食品類に添加できない状況にある。従って、骨粗鬆症
という疾病の性質上、長期的に経口摂取することがで
き、直接的に骨に作用し、その予防または治療効果が期
待できるような経口投与製剤あるいは飲食品の開発が望
まれている。However, when these calcium is ingested as food together with other ingredients, its absorption rate is 50%.
It is said that more than half is not absorbed and is discharged outside the body. In addition, since calcium absorbed in the body has different affinity to bone depending on its form and the types of other nutrients taken at the same time, it may not show the effects of improving bone metabolism and bone strengthening. In addition, vitamin D 3 and calcitonin preparations are known as drugs for treating osteoporosis and bone strengthening. However, when these drugs are used, side effects such as tinnitus, headache, and loss of appetite may be associated. Further, at present, the substances used as these medicines cannot be added to foods and drinks in terms of safety and economy. Therefore, due to the nature of the disease called osteoporosis, it is desired to develop an orally-administered preparation or a food or drink that can be taken orally for a long period of time and directly acts on bone, and its preventive or therapeutic effect can be expected. .
【0004】骨強化のためには、十分な量のカルシウム
を摂取する必要がある。一般に、カルシウムを豊富に含
有する食品として、乳および乳製品、小魚、貝類などが
あるが、中でも近年乳由来のカルシウムが生体に効率良
く利用されることが知られるようになってきた[V. K. K
ansal and S. Chandhary, Milchwissenschaft, 37, 261
(1982)]。カルシウムを摂取するためには、乳および乳
製品を多く摂取すればよいことになるが、栄養のバラン
スやカロリーの摂取量を考えると、むやみに乳製品を摂
取することはできないという問題がある。It is necessary to ingest a sufficient amount of calcium for bone strengthening. In general, foods rich in calcium include milk and dairy products, small fish, shellfish, etc. Among them, it has become known in recent years that milk-derived calcium can be effectively utilized by the living body [VK K
ansal and S. Chandhary, Milchwissenschaft, 37, 261
(1982)]. In order to ingest calcium, it is sufficient to ingest a large amount of milk and dairy products, but in view of nutritional balance and calorie intake, there is a problem that dairy products cannot be indiscriminately ingested.
【0005】[0005]
【発明が解決しようとする課題】本発明者らはこれまで
食品素材に含まれる骨強化作用を示す画分について探索
を進め、乳中に含まれる塩基性タンパク質画分に骨強化
作用があることを明らかにした。この塩基性タンパク質
は、乳あるいは乳由来の原料を陽イオン交換体と接触さ
せることで容易に得られ、また得られた塩基性タンパク
質を経口摂取することで骨を強化することができること
を見い出し、先に骨強化剤として出願(特願平6-261609
号)した。そして、この塩基性タンパク質画分の実際の
食生活における有効な活用方法を更に検討したところ、
これを乳由来のカルシウムと同時に摂取すると乳カルシ
ウムの吸収率が向上し、骨強化作用が大幅に増強される
ことを見い出し、本発明を完成させるに至った。DISCLOSURE OF THE INVENTION The inventors of the present invention have been searching for fractions having a bone-reinforcing action contained in food materials, and that the basic protein fraction contained in milk has a bone-reinforcing action. Revealed. It was found that this basic protein can be easily obtained by contacting milk or a raw material derived from milk with a cation exchanger, and that bone can be strengthened by orally ingesting the obtained basic protein, First applied as a bone strengthening agent (Japanese Patent Application No. 6-261609)
No.) And when further studying the effective utilization method of this basic protein fraction in the actual diet,
It was found that when this is ingested at the same time as milk-derived calcium, the absorption rate of milk calcium is improved and the bone strengthening effect is significantly enhanced, and the present invention has been completed.
【0006】[0006]
【課題を解決するめの手段】本発明は、乳由来の塩基性
タンパク質および乳由来のカルシウムを含有し、骨強化
作用を有する組成物である。本発明の骨強化作用を有す
る組成物は、経口投与製剤あるいは飲食品の形態で用い
られる。本発明の組成物は、乳由来の塩基性タンパク質
画分を固形換算で50mg/100g 以上および乳由来のカルシ
ウムを250 mg/100g 以上含有している。食品の形態にお
いても、固形換算で乳由来の塩基性タンパク質画分を50
mg/100g 以上、および乳由来のカルシウムを250 mg/100
g 以上含有している。また本発明組成物は、飲料の形態
においては、固形換算で乳由来の塩基性タンパク質画分
を77mg/100g 以上、および乳由来のカルシウムを380mg/
100g以上含有することからなる。また本発明組成物を構
成する乳由来の塩基性タンパク質画分のアミノ酸組成中
に、塩基性アミノ酸を15重量%以上含有する。また本発
明組成物を構成する乳由来の塩基性タンパク質画分は、
インスリン様成長因子−1を含有している。また本発明
組成物を構成する乳由来の塩基性タンパク質画分は、イ
ンスリン様成長因子−1を、固形換算で200 μg/100g以
上含有している。また本発明組成物を構成するは乳由来
の塩基性タンパク質画分は、乳または乳由来の原料を陽
イオン交換樹脂に接触させた後、塩濃度0.1 〜1.0 Mの
溶液で溶出した画分である。DISCLOSURE OF THE INVENTION The present invention is a composition containing a milk-derived basic protein and milk-derived calcium and having a bone-reinforcing action. The composition having a bone-reinforcing effect of the present invention is used in the form of an orally-administered preparation or a food or drink. The composition of the present invention contains 50 mg / 100 g or more of milk-derived basic protein fraction and 250 mg / 100 g or more of milk-derived calcium in terms of solids. Even in the form of food, 50% of the basic protein fraction derived from milk is calculated on a solid basis.
mg / 100g or more and milk-derived calcium 250 mg / 100
Contains more than g. Further, the composition of the present invention, in the form of a beverage, the milk-derived basic protein fraction is 77 mg / 100 g or more in terms of solid, and the milk-derived calcium is 380 mg /
Consists of more than 100g. Further, the amino acid composition of the milk-derived basic protein fraction constituting the composition of the present invention contains 15% by weight or more of a basic amino acid. Further, the milk-derived basic protein fraction constituting the composition of the present invention,
It contains insulin-like growth factor-1. The milk-derived basic protein fraction constituting the composition of the present invention contains insulin-like growth factor-1 in an amount of 200 μg / 100 g or more in terms of solid. The milk-derived basic protein fraction constituting the composition of the present invention is a fraction obtained by contacting milk or a milk-derived raw material with a cation exchange resin and then eluting with a solution having a salt concentration of 0.1 to 1.0 M. is there.
【0007】以下、本発明について詳細に説明する。本
発明で用いられる乳由来の塩基性タンパク質は、牛乳、
人乳、山羊乳、羊乳など哺乳類の乳から得られるもので
あって、直接的に骨に作用し、乳由来のカルシウムと同
時に摂取することで、その骨強化作用を大幅に増強する
ことができるものである。本発明の骨強化作用を有する
組成物は、乳由来の塩基性タンパク質と乳由来のカルシ
ウムとを同時に含有していれば経口投与製剤の形態ある
いは飲食品の形態で用いることができる。経口投与製剤
の形態としては、例えば錠剤、カプセル剤、顆粒剤、散
剤、丸剤、ドリンク剤、シロップ剤等を挙げることがで
きる。また飲食品は、いかなる形態のものとしてもよい
が、例えばプロセスチーズや発酵乳あるいは加工食品等
を挙げることができる。また飲料では、飲用乳やドリン
クヨーグルトあるいはコーヒー飲料や果汁等を挙げるこ
とができ、最終製品中でその活性が失われない製造方法
によって得られた飲食品であれば全く制限されない。乳
が主原料である飲食品では、その中に乳由来のカルシウ
ムが本来含まれており、この場合には新たに乳由来のカ
ルシウムを添加せずに、この乳由来のカルシウムを有効
成分とすることも可能であり、また更に強化しても良
い。Hereinafter, the present invention will be described in detail. The basic protein derived from milk used in the present invention is milk,
It is obtained from mammalian milk such as human milk, goat milk, and sheep milk. It acts directly on bones, and by ingesting it simultaneously with milk-derived calcium, its bone strengthening effect can be greatly enhanced. It is possible. The composition having a bone-reinforcing effect of the present invention can be used in the form of an orally-administered preparation or in the form of a food or drink as long as it contains a milk-derived basic protein and milk-derived calcium at the same time. Examples of the form of the oral administration preparation include tablets, capsules, granules, powders, pills, drinks, syrups and the like. The food and drink may be in any form, and examples thereof include process cheese, fermented milk, and processed foods. Examples of drinks include drinkable milk, drink yogurt, coffee drinks, fruit juices, etc., and there is no limitation as long as they are foods and drinks obtained by a production method in which the activity of the final product is not lost. In foods and drinks in which milk is the main raw material, milk-derived calcium is inherently contained therein, and in this case, without adding new milk-derived calcium, this milk-derived calcium is used as an active ingredient. It is also possible and may be further strengthened.
【0008】乳由来の塩基性タンパク質を調製する方法
としては、アルギン酸ゲルを用いる方法( 特開昭61-246
198 号公報) 、硫酸化エステル化合物を用いる方法( 特
開昭63-255300 号公報) 、無機の多孔質粒子を用いる方
法( 特開平 1-86839号公報)、陽イオン交換体を用いる
方法( 特開平 5-202098 号公報) 、ウシインスリン様成
長因子−1含有物の製造方法( 特願平6-85333 号公報)
等があるが、本発明に使用する乳由来の塩基性タンパク
質としては、上記の特願平6-85333 号に記載されている
ウシインスリン様成長因子−1含有物の製造方法によっ
て得られたもの、あるいは乳または乳由来の原料を陽イ
オン交換樹脂に接触させた後、樹脂に吸着した画分を塩
溶液で溶出した画分を使用することが好ましい。As a method for preparing a milk-derived basic protein, a method using alginic acid gel (JP-A-61-246)
198), a method using a sulfated ester compound (JP-A-63-255300), a method using inorganic porous particles (JP-A-1-86839), and a method using a cation exchanger (Patent Document 1). (Kaihei 5-202098), a method for producing a bovine insulin-like growth factor-1 containing substance (Japanese Patent Application No. 6-85333)
, Etc., the milk-derived basic protein used in the present invention is obtained by the method for producing a bovine insulin-like growth factor-1 containing substance described in Japanese Patent Application No. 6-85333. Alternatively, it is preferable to use a fraction obtained by contacting milk or a raw material derived from milk with a cation exchange resin and then eluting a fraction adsorbed on the resin with a salt solution.
【0009】上記の乳または乳由来の原料を陽イオン交
換樹脂に接触させた後、樹脂に吸着した画分を塩溶液で
溶出する場合には、pHが4〜8にある脱脂乳や乳清な
どの乳原料を陽イオン交換樹脂(好ましくは、スルホン
酸基を交換基として持つもの)と接触させた後、樹脂を
塩濃度が0.1M以上1.0M以下の例えば塩化ナトリウムや炭
酸ナトリウムあるいはクエン酸ナトリウム等の水溶液で
溶出し、溶出画分を回収する。乳原料のpHが4以下で
あると、塩基性タンパク質以外のタンパク質も陽イオン
交換体に吸着して得られた画分中の塩基性タンパク質含
有率が低下し、一方pHが8以上では塩基性タンパク質
の回収率が低下する。陽イオン交換体からの塩基性タン
パク質の溶出に必要な塩濃度は、1.0M以下であるが、溶
出液の塩濃度が0.1M未満の場合には溶出が不十分となり
好ましくない。そして得られた画分を、イオン交換法、
逆浸透法、限外濾過法、電気透析法などの手段で脱塩お
よび濃縮し、必要に応じて乾燥して粉末化することがで
きる。このようにして得られた塩基性タンパク質画分中
には、固形重量で約40%以上のラクトフェリンおよびラ
クトパーオキシダーゼを含有している。また骨芽細胞を
活性化し、骨を強化する作用を有するインスリン様成長
因子−1(以下 IGF−1という)[ 斉藤史郎ら、日
本臨床, 48, 2779 (1990)]も固形100g当たり200 〜500
μg 含有している。そしてこの画分のアミノ酸組成中に
15重量%以上の塩基性アミノ酸を含有している。When the above-mentioned milk or milk-derived raw material is brought into contact with a cation exchange resin and then the fraction adsorbed on the resin is eluted with a salt solution, skim milk or whey having a pH of 4 to 8 is obtained. After contacting a milk material such as cation exchange resin (preferably one having a sulfonic acid group as an exchange group), the resin has a salt concentration of 0.1 M or more and 1.0 M or less, such as sodium chloride, sodium carbonate or citric acid. Elute with an aqueous solution such as sodium and collect the eluted fraction. When the pH of the dairy raw material is 4 or less, the basic protein content in the fraction obtained by adsorbing proteins other than the basic protein to the cation exchanger decreases, while when the pH is 8 or more, the basic protein content is basic. Protein recovery is reduced. The salt concentration required for elution of the basic protein from the cation exchanger is 1.0 M or less, but if the salt concentration of the eluate is less than 0.1 M, elution will be insufficient, which is not preferable. The obtained fraction is then subjected to an ion exchange method,
It can be desalted and concentrated by a means such as a reverse osmosis method, an ultrafiltration method, an electrodialysis method, etc., and if necessary, dried and powdered. The basic protein fraction thus obtained contains about 40% or more by weight of solids of lactoferrin and lactoperoxidase. Insulin-like growth factor-1 (hereinafter referred to as IGF-1), which has an action of activating osteoblasts and strengthening bone, [Shiro Saito et al., Japan Clinic, 48, 2779 (1990)] is 200 to 500 per 100 g of solid.
Contains μg. And in the amino acid composition of this fraction
It contains 15% by weight or more of basic amino acids.
【0010】本発明組成物中の乳由来のカルシウムは、
例えば、乳のカゼインに酸を添加してpH5.5 以下と
し、該カゼインからカゼイン結合性カルシウムおよびコ
ロイド状カルシウムを選択的に分離し、回収する乳由来
のカルシウム剤の製造方法(特開平6-125740号公報)に
よって得られたカルシウム、あるいは市販のラクトバル
(DMV社製) や中外CA-18(中外製薬社製) 等の乳由来のカ
ルシウムを用いることができる。The milk-derived calcium in the composition of the present invention is
For example, a method for producing a milk-derived calcium agent by adding acid to milk casein to adjust the pH to 5.5 or less, selectively separating casein-binding calcium and colloidal calcium from the casein, and recovering the same (JP-A-6- 125740), calcium obtained according to Japanese Patent No.
Milk-derived calcium such as (manufactured by DMV) or Chugai CA-18 (manufactured by Chugai Pharmaceutical) can be used.
【0011】このようにして得られた乳由来の塩基性タ
ンパク質と乳由来のカルシウムを用いて経口投与製剤を
製造する場合には、有効成分としての乳由来の塩基性タ
ンパク質と乳由来のカルシウムとを、製剤の分野におい
て通常用いられる製剤成分、例えば増量剤、希釈剤、溶
剤及び充填剤等のような賦形剤;溶解補助剤、可溶化
剤、乳化剤、懸濁化剤、分散剤、結合剤、滑沢剤、コー
ティング剤及び徐放化剤等のような補助剤;または抗酸
化剤、保存剤、光沢剤、甘味剤、着色剤、着香剤等の添
加剤と混合し、常法により適当な形態に成形したり、ま
たは液剤とすることができる。経口投与製剤は、乳由来
の塩基性タンパク質と乳由来のカルシウムの他に、その
他の一種または2種以上の薬効成分を含むものであって
もよい。When an oral administration preparation is produced using the milk-derived basic protein and milk-derived calcium thus obtained, the milk-derived basic protein and the milk-derived calcium as active ingredients are used. Are ingredients commonly used in the field of formulation, for example, excipients such as fillers, diluents, solvents and fillers; solubilizers, solubilizers, emulsifiers, suspending agents, dispersants, binding agents. Auxiliary agents such as agents, lubricants, coating agents and sustained-release agents; or additives such as antioxidants, preservatives, brighteners, sweeteners, coloring agents, flavoring agents, etc. According to the above, it can be molded into an appropriate form or can be made into a liquid agent. The orally-administered preparation may contain, in addition to the milk-derived basic protein and the milk-derived calcium, one or more other medicinal components.
【0012】また食品へ配合した時、後述する動物実験
の結果から明らかなように、固形100g当たり塩基性タン
パク質を50mg以上と乳由来のカルシウムを250mg 以上と
を同時に配合し、これを摂取した場合に骨強化作用が認
められる。飲料では、固形100g当たり、塩基性タンパク
質を77mg以上と乳由来のカルシウムを380mg 以上とを配
合した場合に同様の効果が認められる。なお、この様に
乳由来塩基性タンパク質ならびに乳由来カルシウムを配
合した飲食品中には、IGF−1が固形100g当たり0.5
μg 以上含まれている。通常の乳製品をベースに乳由来
の塩基性タンパク質を配合する場合には、例えば牛乳や
醗酵乳には固形分100g当たり900mg 以上の乳由来のカル
シウムが含まれており、またプロセスチーズには約620m
g 程度の乳由来のカルシウムが含まれているため、これ
らに所定量の乳由来塩基性タンパク質のみを添加しても
骨強化作用は期待できる。一方、全く乳成分を含まない
食品や乳成分の含量が一定量以下の食品では、乳由来の
塩基性タンパク質と同時に乳由来のカルシウムも添加し
なければならない。これらの添加方法については特に制
限は無く、通常の方法が用いられる。また、しばしば、
生理活性タンパク質は、加熱により失活し、その効力を
失うことが多いが、塩基性タンパク質画分については、
通常の殺菌温度まで加熱してもその効力を失うことはな
い。飲用牛乳に乳由来の塩基性タンパク質を配合する場
合では、まず生乳100ml 当たり10mg以上の濃度となるよ
うに乳由来の塩基性タンパク質を加え、ホモゲナイズ
し、殺菌、冷却した後、容器に充填する。Further, when blended into food, as is clear from the results of animal experiments described later, when 100 mg of solid protein and 50 mg or more of basic protein and 250 mg or more of calcium derived from milk are simultaneously blended and ingested Bone strengthening effect is recognized in the. In beverages, the same effect is observed when 77 mg or more of basic protein and 380 mg or more of calcium derived from milk are mixed per 100 g of solid. In the food and drink containing the milk-derived basic protein and the milk-derived calcium as described above, IGF-1 is 0.5
Included over μg. When blending milk-derived basic proteins based on ordinary dairy products, for example, milk or fermented milk contains 900 mg or more milk-derived calcium per 100 g of solid content, and processed cheese contains approximately 620m
Since it contains about g of calcium derived from milk, bone-strengthening action can be expected even if only a predetermined amount of milk-derived basic protein is added to them. On the other hand, in foods containing no milk components or foods containing a certain amount of milk components or less, milk-derived basic proteins must be added together with milk-derived calcium. The addition method of these is not particularly limited, and a usual method is used. Also often
Bioactive proteins are often inactivated by heating and lose their potency, but regarding the basic protein fraction,
Heating to the normal sterilization temperature does not lose its efficacy. When milk-derived basic protein is added to drinking milk, first, milk-derived basic protein is added to a concentration of 10 mg or more per 100 ml of raw milk, homogenized, sterilized, and cooled, and then filled in a container.
【0013】また発酵乳においては、原料乳、例えば脱
脂乳または脱脂粉乳に水を加えて溶解した物を加熱殺菌
後冷却し、これに所定量の乳由来の塩基性タンパク質を
添加し、ストレプトコッカス・ラクチス・サブスピーシ
ーズ・サーモフィルス(S. lactis.sp.thermophilus) 、
ラクトバチルス・ヘルベティクス(L. helveticus )、
ラクトバチルス・クレモリス(L. cremoris )、ラクト
バチルス・アシドフイルス(L. acidophilus)あるいは
ビフイドバクテリウム・スピーシーズ(Bifidobacteriu
m species )等の乳酸菌の一種または二種以上を接種し
て発酵させる。そして乳酸酸度が0.8 〜1.5 %あるいは
pHが4.0 〜4.5 になったら、10℃以下に冷却する。In fermented milk, a raw material milk, for example skim milk or skim milk powder, dissolved in water and dissolved is heated and sterilized, and then cooled, and a predetermined amount of milk-derived basic protein is added thereto to obtain Streptococcus. Lactis subspecies thermophilus (S. lactis .sp. Thermophilus ),
Lactobacillus helveticus ,
Lactobacillus cremoris ( L. cremoris ), Lactobacillus acidophilus ( L. acidophilus ) or Bifidobacterial species ( Bifidobacteriu)
Inoculate with one or more lactic acid bacteria such as m species) to ferment. When the lactic acid acidity is 0.8 to 1.5% or the pH is 4.0 to 4.5, the temperature is cooled to 10 ° C or lower.
【0014】発酵乳に乳由来の塩基性タンパク質を添加
する方法としては、上記したようにスターターカルチャ
ーに塩基性タンパク質を添加した後、乳培地に接種して
発酵させる方法、または加熱殺菌後の乳培地に乳酸菌を
接種して発酵させ、その後所定量の乳由来の塩基性タン
パク質を添加する方法がある。しかし、スターターカル
チャーに塩基性タンパク質を添加した後、発酵させる方
法が、得られた発酵乳中で塩基性タンパク質が均一に分
散しているため好ましい。これは、例えば撹拌型ヨーグ
ルトでは、発酵後に塩基性タンパク質を添加しても発酵
乳中に均一に分散することができなかったり、また静置
型ヨーグルトでは、個食容器にスターターカルチャーを
含有する培地を充填して発酵させるため、実質上乳由来
の塩基性タンパク質を添加することができないという問
題がある。As a method for adding a milk-derived basic protein to the fermented milk, as described above, the basic protein is added to the starter culture and then inoculated into a milk medium to ferment, or the milk after heat sterilization. There is a method in which lactic acid bacteria are inoculated into the medium to ferment it, and then a predetermined amount of milk-derived basic protein is added. However, the method of fermenting after adding the basic protein to the starter culture is preferable because the basic protein is uniformly dispersed in the obtained fermented milk. This is, for example, in stirring type yogurt, even if it is not possible to uniformly disperse in the fermented milk even if basic protein is added after fermentation, or in the standing type yogurt, the medium containing the starter culture in the individual food container. Since it is filled and fermented, there is a problem that the basic protein derived from milk cannot be added substantially.
【0015】乳由来の塩基性タンパク質を発酵乳に利用
する場合には、スターターカルチャーへの乳由来の塩基
性タンパク質の添加量は、最終製品中の乳由来の塩基性
タンパク質の濃度から逆算して求める。例えば、最終製
品中の乳由来の塩基性タンパク質の濃度を固形100g当た
り50mgとし、スターターカルチャーを5%添加する場合
には、スターター中への乳由来の塩基性タンパク質の添
加量は、固形100g当たり100mg になる。ヨーグルトを製
造する場合には、常法に従って乳脂肪分を3.5 %程度に
標準化した生乳を培地とし、これを殺菌した後、上記の
ように調製したスターターカルチャーを接種して発酵さ
せる。またサワークリームを製造する場合には、培地と
して乳脂肪45%程度のクリームが用いられ、クワルクを
製造する場合には、培地として脱脂乳が用いられる。培
地の殺菌条件には、特に制限がなく、90℃、10分間、あ
るいは97℃、15秒間といった通常行われている条件が採
用できる。スターターカルチャーの接種は、培地を培養
温度( 製品によって異なるが、25〜45℃程度) まで冷却
した後、乳量の1 〜10%程度添加する。接種後の充填、
発酵、フレーバリング、冷却等の工程は、常法に従って
実施することができる。When the milk-derived basic protein is used in fermented milk, the amount of the milk-derived basic protein added to the starter culture is calculated by calculating backward from the concentration of the milk-derived basic protein in the final product. Ask. For example, if the concentration of milk-derived basic protein in the final product is 50 mg per 100 g of solid and 5% of starter culture is added, the amount of milk-derived basic protein added to the starter is 100 g of solid. It becomes 100 mg. In the case of producing yogurt, according to a conventional method, raw milk having a milk fat content standardized to about 3.5% is used as a culture medium, which is sterilized, and then the starter culture prepared as described above is inoculated and fermented. When sour cream is produced, a cream containing about 45% milk fat is used as a medium, and when producing quark, skim milk is used as a medium. The sterilization conditions of the medium are not particularly limited, and commonly used conditions such as 90 ° C. for 10 minutes or 97 ° C. for 15 seconds can be adopted. To inoculate the starter culture, cool the medium to the culture temperature (about 25 to 45 ℃, depending on the product), and then add about 1 to 10% of the milk yield. Filling after inoculation,
Steps such as fermentation, flavoring, cooling and the like can be carried out according to conventional methods.
【0016】プロセスチーズに乳由来の塩基性タンパク
質を配合するには、原料チーズを乳化する際に溶融塩等
の副原料と一緒に加えても良いし、またあらかじめ添加
水や溶融塩に添加して原料チーズとよく混合し、その後
乳化する方法が採用できる。乳化温度は、通常のプロセ
スチーズを製造する方法と同じ乳化温度でよく、水分含
量、pHともに特に制限されることはない。In order to mix the basic protein derived from milk into the processed cheese, it may be added together with an auxiliary material such as a molten salt when emulsifying the raw material cheese, or may be added in advance to the added water or the molten salt. It is possible to employ a method in which the raw material cheese is mixed well and then emulsified. The emulsification temperature may be the same emulsification temperature as in the method for producing an ordinary processed cheese, and the water content and pH are not particularly limited.
【0017】次に、実施例及び試験例を示して本発明を
詳細に説明する。なお、以下に示す実施例は、本発明を
より具体的に示す例であり、これにより本発明が限定さ
れるものではない。Next, the present invention will be described in detail by showing Examples and Test Examples. The examples described below are examples showing the present invention more specifically, and the present invention is not limited thereto.
【0018】[0018]
【実施例1】塩基性タンパク質の調製 陽イオン交換樹脂のスルホン化キトパール( 富士紡績株
式会社製)400g を充填したカラム( 直径5cm ×高さ30c
m) を脱イオン水で十分洗浄した後、このカラムに未殺
菌脱脂乳40リットル(pH6.7) を流速25ml/minで通液し
た。通液後、このカラムを脱イオン水で十分洗浄し、0.
98M 塩化ナトリウムを含む0.02M 炭酸緩衝液(pH7.0) で
樹脂に吸着した塩基性タンパク質画分を溶出した。そし
て、この溶出液を逆浸透膜により脱塩し、濃縮した後、
凍結乾燥して粉末状の塩基性タンパク質画分21g を得
た。[Example 1] Preparation of basic protein Column packed with 400 g of cation exchange resin sulfonated chitopearl (manufactured by Fuji Spinning Co., Ltd.) (diameter 5 cm x height 30 c
m) was thoroughly washed with deionized water, and then 40 liters of unsterilized skim milk (pH 6.7) was passed through this column at a flow rate of 25 ml / min. After passing, wash the column thoroughly with deionized water and
The basic protein fraction adsorbed on the resin was eluted with 0.02M carbonate buffer (pH 7.0) containing 98M sodium chloride. Then, after desalting this eluate with a reverse osmosis membrane and concentrating it,
Lyophilization gave 21 g of powdery basic protein fraction.
【0019】塩基性タンパク質画分の成分組成 上記で得られた、塩基性タンパク質画分について、常法
に従い、その成分組成を分析した。その結果を表1に示
す。 Component Composition of Basic Protein Fraction The component composition of the basic protein fraction obtained above was analyzed by a conventional method. Table 1 shows the results.
【0020】[0020]
【表1】 [Table 1]
【0021】塩基性タンパク質画分中のタンパク質組成 上記で得られた塩基性タンパク質画分について、常法に
従い、そのタンパク質組成を分析した。ラクトフェリン
およびラクトパーオキシダーゼ含量については通常のエ
ンザイムイムノアッセイ法で、IGF-1 含量についてはラ
ジオイムノアッセイ法で測定した。その結果を表2に示
す。 Protein Composition in Basic Protein Fraction The basic protein fraction obtained above was analyzed for protein composition according to a conventional method. The lactoferrin and lactoperoxidase contents were measured by a usual enzyme immunoassay method, and the IGF-1 content was measured by a radioimmunoassay method. The results are shown in Table 2.
【0022】[0022]
【表2】 [Table 2]
【0023】塩基性タンパク質画分中のアミノ酸組成 上記で得られた塩基性タンパク質画分について、常法に
従い、そのアミノ酸組成を分析した。その結果を表3に
示す。 Amino Acid Composition in Basic Protein Fraction The amino acid composition of the basic protein fraction obtained above was analyzed by a conventional method. Table 3 shows the results.
【0024】[0024]
【表3】 [Table 3]
【0025】[0025]
【実施例2】実施例1で得られた乳由来塩基性タンパク
質を用いて、飲用牛乳を製造した。生乳100cc 当たり、
それぞれ2 、 10 、 20 、 40 、100 mgの乳由来の塩基
性タンパク質を加え、120kg/cm2 でホモゲナイズした
後、120 ℃で 4秒間殺菌した。その後、常法に従って冷
却、充填を行った。得られた飲用牛乳は、乳由来の塩基
性タンパク質を含んでいても、風味は通常の飲用牛乳と
全く同様であった。飲用牛乳中のカルシウム含量は130m
g/100ml (固形換算で約1030mg/100g)で、またIGF-1 含
量はラジオイムノアッセイで測定した結果、表4に示す
通りであった。Example 2 The milk-derived basic protein obtained in Example 1 was used to produce drinking milk. Per 100cc of raw milk,
2, 10, 20, 40, and 100 mg of basic protein derived from milk were added, homogenized at 120 kg / cm 2 , and sterilized at 120 ° C for 4 seconds. Then, cooling and filling were performed according to a conventional method. Even if the obtained drinking milk contained basic protein derived from milk, the flavor was completely the same as that of ordinary drinking milk. Calcium content in drinking milk is 130m
It was g / 100 ml (about 1030 mg / 100 g in terms of solid), and the IGF-1 content was measured by radioimmunoassay, and as shown in Table 4.
【0026】[0026]
【表4】 [Table 4]
【0027】[0027]
【実施例3】実施例1で得られた塩基性タンパク質を用
いて、ヨーグルトを製造した。脱脂粉乳を固形率が12%
となるように水に溶解し、これにヨーグルト100 g 当た
り、それぞれ2 、10、 20 、 40 、100mg になるように
乳由来の塩基性タンパク質を加え、これを90℃で20分間
加熱殺菌した後、25℃に冷却し、L. acidophilusとS.th
ermophilus を接種した。乳酸酸度が1.0 %、pHが4.3
になった時点で5℃に冷却した。この様にして得られ
たスターターカルチャーを、殺菌した脂肪分3.5 %の生
乳に5%接種した。スターターを接種後、発酵、フレー
バリング、冷却を常法どおり行った。また、得られたヨ
ーグルトは、塩基性タンパク質画分を含有していても、
風味、物性、食感には全く影響を及ぼさなかった。ヨー
グルト中のカルシウム含量は、130mg/100g( 固形換算で
約1030mg/100g)で、またIGF-1 含量はラジオイムノアッ
セイで測定した結果、表5に示す通りであった。Example 3 Yogurt was produced using the basic protein obtained in Example 1. Skim milk powder has a solid content of 12%
Dissolve in water so that the amount of basic protein derived from milk is 2, 10, 20, 40, and 100 mg per 100 g of yogurt, and sterilize by heating at 90 ° C for 20 minutes. , Cooled to 25 ℃, L. acidophilus and S. th
ermophilus was inoculated. Lactic acid degree is 1.0%, pH is 4.3
When it became, it was cooled to 5 ° C. 5% of the starter culture thus obtained was inoculated into sterilized raw milk having a fat content of 3.5%. After inoculating the starter, fermentation, flavoring and cooling were carried out in the usual manner. Also, the obtained yogurt, even if it contains a basic protein fraction,
It had no effect on flavor, physical properties and texture. The calcium content in yogurt was 130 mg / 100 g (about 1030 mg / 100 g in terms of solid), and the IGF-1 content was measured by radioimmunoassay, and as shown in Table 5.
【0028】[0028]
【表5】 [Table 5]
【0029】[0029]
【実施例4】実施例1で得られた塩基性タンパク質画分
を用いて、プロセスチーズを製造した。原料チーズとし
て、ゴーダチーズとチェダーチーズを1:1の割合で混
合し、これに溶融塩としてクエン酸ナトリウムを原料チ
ーズに対して2%、水を10%およびプロセスチーズ100g
当たり、10、20、50、100 、150mg になるように乳由来
の塩基性タンパク質画分を配合し、乳化温度85℃で常法
に従って乳化した。乳化後、チーズをカルトンに充填
し、2昼夜5℃で冷却した。得られたプロセスチーズの
カルシウム含量は、620mg/100gで、IGF-1 含量は、ラジ
オイムノアッセイ法で測定した結果、表6に示す通りで
あった。また、得られたプロセスチーズは、塩基性タン
パク質画分を含有していても、風味、物性、食感には全
く影響を及ぼさなかった。Example 4 Using the basic protein fraction obtained in Example 1, processed cheese was produced. As raw material cheese, gouda cheese and cheddar cheese were mixed at a ratio of 1: 1 and 2% of sodium citrate as a molten salt was added to the raw material cheese, 10% of water and 100 g of processed cheese.
The basic protein fraction derived from milk was blended so that the amount per unit was 10, 20, 50, 100, and 150 mg, and the mixture was emulsified according to a conventional method at an emulsification temperature of 85 ° C. After emulsification, the cheese was filled in a carton and cooled at 5 ° C for 2 days and nights. The calcium content of the obtained processed cheese was 620 mg / 100 g, and the IGF-1 content was as shown in Table 6 as a result of measurement by the radioimmunoassay method. Moreover, even if the obtained processed cheese contained the basic protein fraction, it did not affect flavor, physical properties, and texture at all.
【0030】[0030]
【表6】 ─────────────────────────
──────────[Table 6] ─────────────────────────
──────────
【0031】[0031]
【実施例5】実施例1で得られた乳由来の塩基性タンパ
ク質粉末および乳由来のカルシウムとして、ラクトバル
(DMV社製) の粉末を、ゼラチンよりなるソフトカプセル
中に一錠当たり乳由来の塩基性タンパク質が 50mg およ
び乳由来のカルシウムが250mg となるように充填して骨
強化作用を有する経口投与製剤を得た。Example 5 As the milk-derived basic protein powder and milk-derived calcium obtained in Example 1, lactobal
(DMV) powder was filled in a soft capsule made of gelatin so that 50 mg of milk-derived basic protein and 250 mg of milk-derived calcium were added per capsule to give an orally-administered preparation having bone-reinforcing action. It was
【0032】次に動物実験により本発明の効果を確認し
た試験例を示す。Next, test examples in which the effects of the present invention have been confirmed by animal experiments will be shown.
【試験例1】実施例1で得られた乳由来の塩基性タンパ
ク質および乳由来のカルシウムとして、ラクトバル(DMV
社製) を用い、動物実験により、その骨強化作用を発現
するのに必要な乳由来の塩基性タンパク質の量を検討し
た。実験動物には4週齢のSD系雌ラットを用いた。1週
間の予備飼育の後、卵巣摘出手術を施し、その後、カル
シウム欠乏食で5週間飼育して動物実験に供した。尚、
卵巣を摘出し、カルシウム欠乏食で5週間飼育したラッ
トは、明らかに、骨粗鬆症状態にあった。この骨粗鬆症
状態を惹起したラットを、1群6匹づつ(以下の実験例
についても同じ)、表7に示す飼料で飼育した。[Test Example 1] As the milk-derived basic protein and milk-derived calcium obtained in Example 1, lactobal (DMV
The amount of basic protein derived from milk necessary for expressing the bone-reinforcing effect was examined by an animal experiment. Four-week-old SD female rats were used as experimental animals. After preliminarily breeding for 1 week, an oophorectomy operation was performed, and then the animals were fed with a calcium deficient diet for 5 weeks and used for animal experiments. still,
The rats that had their ovaries removed and were kept on a calcium-deficient diet for 5 weeks were clearly in an osteoporotic state. The rats in which this osteoporotic state was induced were bred by the diet shown in Table 7 (6 rats per group) (the same applies to the following experimental examples).
【0033】[0033]
【表7】 [Table 7]
【0034】4週間後、各試験群のラットの両側大腿骨
を摘出し、骨破断力測定装置で骨強度を測定した。その
結果を図1に示す。これによると、同量の乳由来のカル
シウムを添加した場合、飼料100g中に乳由来の塩基性タ
ンパク質を50mg以上配合した群(D群、 E群) では、コン
トロール群(A群) に比べ大腿骨破断応力が統計的(Tukey
-Kramer 法) に有意に高い値を示した。After 4 weeks, both femurs of the rats in each test group were excised and the bone strength was measured by a bone breaking force measuring device. The result is shown in FIG. According to this, when the same amount of calcium derived from milk was added, in the group (D group, E group) in which 50 mg or more of basic protein derived from milk was added to 100 g of feed, the thigh was compared to the control group (Group A). Bone fracture stress is statistical (Tukey
-Kramer method) showed a significantly high value.
【0035】[0035]
【試験例2】実施例1で得られた乳由来の塩基性タンパ
ク質および乳由来のカルシウムとしてラクトバル(DMV社
製) を用い、試験例1と同様の方法で、表8に示した飼
料により動物実験を行い、その骨強化作用を発現するの
に必要な乳由来のカルシウムの量を検討した。また、コ
ントロール群(A〜D 群) には、カルシウム源として炭酸
カルシウムを添加した。Test Example 2 Using the milk-derived basic protein obtained in Example 1 and milk-derived calcium as lactobal (manufactured by DMV), animals were fed in the same manner as in Test Example 1 using the feeds shown in Table 8. An experiment was conducted to examine the amount of milk-derived calcium required to exert the bone strengthening effect. In addition, calcium carbonate was added as a calcium source to the control groups (Groups A to D).
【0036】[0036]
【表8】 [Table 8]
【0037】骨強度の測定は、実験例1と同様の方法で
行った。その結果を図2に示す。一定量の乳由来の塩基
性タンパク質を飼料に配合した場合、乳由来のカルシウ
ムを250mg/100g以上配合した群(G群、H 群) では、コン
トロール群(C群、D 群) に比べ大腿骨破断応力が統計的
(Tukey-Kramer 法) に有意に高い値を示した。The bone strength was measured by the same method as in Experimental Example 1. The result is shown in FIG. When a certain amount of milk-derived basic protein was added to the feed, the femurs in the group (G group, H group) containing 250 mg / 100 g or more of milk-derived calcium were compared to the control group (C group, D group). Breaking stress is statistical
(Tukey-Kramer method) showed a significantly high value.
【0038】[0038]
【試験例3】実施例2で得られた塩基性タンパク質を配
合した飲用牛乳について、試験例1と同様の方法で、表
9に示す飼料を用い乳由来の塩基性タンパク質の添加量
とその骨強化作用の関係を検討した。実施例2で得られ
た乳由来の塩基性タンパク質を含有する飲用牛乳250ml
をあらかじめ凍結乾燥し、この粉末31g を配合した。こ
の飲用牛乳粉末中には、10.3mg/gのカルシウムが含まれ
ていた。また、コントロール群(A群) では、カルシウム
源として炭酸カルシウムを使用し、飲用牛乳粉末の組成
に合わせてカゼイン、ホエータンパク質、乳脂肪、乳糖
を配合した。乳由来の塩基性タンパク質の量は、配合し
た飼料中の乳由来の塩基性タンパク質の量を示すもので
あるが、これを飼料中に配合した飲用牛乳100ml 中の乳
由来の塩基性タンパク質の量に換算すると、A 群は0mg
、B 群は2mg 、C 群は10mg、D群は20mg、E 群は40mg、
F 群は100mg となる。尚、表中の()内の数値は、飲用牛
乳粉末由来のものである。[Test Example 3] Regarding the drinking milk containing the basic protein obtained in Example 2, the amount of the basic protein derived from milk and the bone thereof were added in the same manner as in Test Example 1 using the feed shown in Table 9. The relationship of strengthening action was examined. 250 ml of drinking milk containing the basic protein derived from milk obtained in Example 2
Was freeze-dried in advance, and 31 g of this powder was blended. This drinking milk powder contained 10.3 mg / g of calcium. In the control group (group A), calcium carbonate was used as the calcium source, and casein, whey protein, milk fat, and lactose were added according to the composition of the milk powder for drinking. The amount of milk-derived basic protein indicates the amount of milk-derived basic protein in the mixed feed, and the amount of milk-derived basic protein in 100 ml of drinking milk mixed with this in the feed. When converted to
, B group 2 mg, C group 10 mg, D group 20 mg, E group 40 mg,
F group will be 100 mg. The values in parentheses in the table are derived from drinking milk powder.
【0039】[0039]
【表9】 [Table 9]
【0040】骨強度の測定試験は、試験例1と同様の方
法で行った。その結果を図3に示す。これによると、大
腿骨破断応力は、対照群(A群) に比べ、乳由来の塩基性
タンパク質を飲用牛乳100ml 当たり10mg以上含有するも
のを粉末化して配合した群(C〜F 群) で統計的(Tukey-K
remar 法) に有意に高い値を示した。また、大腿骨破断
応力は、塩基性タンパク質画分の添加量が増加するに従
い高い値を示した。The bone strength measurement test was carried out in the same manner as in Test Example 1. The result is shown in FIG. According to this, compared with the control group (Group A), the femoral fracture stress was statistically compared in the group (C to F group) in which powdered basic protein derived from milk was contained in an amount of 10 mg or more per 100 ml of drinking milk. Target (Tukey-K
The remar method) showed a significantly high value. Further, the femoral fracture stress showed a higher value as the amount of the basic protein fraction added increased.
【0041】[0041]
【試験例4】試験例1と同様の方法で、表10に示す飼
料を用い乳由来のカルシウムの添加量とその骨強化作用
の関係を検討した。尚、飼料中、カゼイン、ホエータン
パク質、乳脂肪、乳糖は、飲用牛乳500cc を凍結乾燥し
て得られる粉末に合わせて配合した。コントロール群(A
群) ではカルシウム源として炭酸カルシウムを、B 〜F
群では炭酸カルシウムに加えて乳由来のカルシウム( ラ
クトバル) を添加した。また、乳由来の塩基性タンパク
質は、100mg/100gであるが、これを飼料に配合した飲用
牛乳粉末の組成から飲用牛乳100cc 中の乳由来の塩基性
タンパク質の量に換算すると20mgとなる。TEST EXAMPLE 4 In the same manner as in Test Example 1, the feeds shown in Table 10 were used to examine the relationship between the amount of milk-derived calcium added and its bone-reinforcing action. In the feed, casein, whey protein, milk fat, and lactose were mixed according to the powder obtained by freeze-drying 500 cc of drinking milk. Control group (A
Group), calcium carbonate as a calcium source, B to F
In the group, milk-derived calcium (lactobar) was added in addition to calcium carbonate. The basic protein derived from milk is 100 mg / 100 g, which is 20 mg when converted to the amount of basic protein derived from milk in 100 cc of drinking milk from the composition of the milk powder for drinking mixed with the feed.
【0042】[0042]
【表10】 [Table 10]
【0043】骨強度の測定は、試験例1と同様に行っ
た。その結果を図4に示す。これによると、大腿骨破断
応力は、同量の乳由来の塩基性タンパク質を添加した対
照群(A群) に比べ、乳由来のカルシウムを飲用牛乳100m
l 当たり50mgに相当する量( 飼料100g当たり250mg)以上
配合した群(E、F 群) で統計的(Tukey-Kremar 法) に有
意に高い値を示した。また、大腿骨破断応力は、乳由来
カルシウムの添加量が増加するに従い高い値を示した。The bone strength was measured in the same manner as in Test Example 1. FIG. 4 shows the results. According to this, the femoral rupture stress was higher than that of the control group (group A) to which the same amount of milk-derived basic protein was added, when milk-derived calcium was added to 100 m of drinking milk.
Statistical (Tukey-Kremar method) values were significantly higher in the groups (E and F groups) containing more than 50 mg / l (250 mg / 100 g of feed). Further, the femoral fracture stress showed a higher value as the amount of milk-derived calcium added increased.
【0044】[0044]
【試験例5】実施例3で得られた乳由来の塩基性タンパ
ク質を配合したヨーグルトについて、試験例1と同様の
方法で、表11に示す飼料を用い、乳由来の塩基性タン
パク質の添加量とその骨強化作用の関係を検討した。
尚、A 群を除いた各飼料に実施例3で得られた乳由来の
塩基性タンパク質を配合したヨーグルト250gを、あらか
じめ凍結乾燥し、粉末31g として配合した。このヨーグ
ルト粉末中には、10.3mg/gのカルシウムが含まれてい
た。また、コントロール群(A群) では、カルシウム源と
して炭酸カルシウムを使用し、ヨーグルト粉末の組成に
合わせてカゼイン、ホエータンパク質、乳脂肪、乳糖を
配合した。乳由来の塩基性タンパク質の量は、配合した
飼料中の乳由来の塩基性タンパク質の量を示すものであ
るが、これを飼料中に配合したヨーグルト100 g 中の乳
由来の塩基性タンパク質の量に換算すると、A 群は0mg
、B 群は2mg 、C 群は10mg、D 群は20mg、E 群は40m
g、F 群は100mg となる。表中の()内の数値はヨーグル
ト粉末由来のものである。[Test Example 5] With respect to the yogurt containing the milk-derived basic protein obtained in Example 3, the feed amount shown in Table 11 was used in the same manner as in Test Example 1, and the added amount of the milk-derived basic protein was added. And the relation between the bone strengthening effect was investigated.
Incidentally, 250 g of yogurt containing the basic protein derived from milk obtained in Example 3 was preliminarily freeze-dried to each feed except for the group A and mixed as powder 31 g. This yogurt powder contained 10.3 mg / g of calcium. In the control group (Group A), calcium carbonate was used as the calcium source, and casein, whey protein, milk fat, and lactose were added according to the composition of the yogurt powder. The amount of milk-derived basic protein indicates the amount of milk-derived basic protein in the mixed feed, and the amount of milk-derived basic protein in 100 g of yogurt mixed with this in the feed. When converted to
, B group 2 mg, C group 10 mg, D group 20 mg, E group 40 m
The g and F groups will be 100 mg. Numerical values in parentheses in the table are derived from yogurt powder.
【0045】[0045]
【表11】 [Table 11]
【0046】骨強度の測定は、試験例1と同様な方法で
行った。その結果を図5に示す。これによると、大腿骨
破断応力は、対照群(A群) に比べ、乳由来の塩基性タン
パク質を100g当たり10mg以上含有するヨーグルトを粉末
化して配合した群(C〜F 群)で統計的(Tukey-Kremar 法)
に有意に高い値を示した。また、大腿骨破断応力は、
塩基性タンパク質画分の添加量が増加するに従い高い値
を示した。The bone strength was measured by the same method as in Test Example 1. The result is shown in FIG. According to this, compared with the control group (Group A), the femoral fracture stress was statistically higher in the group (C to F group) in which yogurt containing 10 mg or more of milk-derived basic protein per 100 g was pulverized and mixed (Group C to F). (Tukey-Kremar method)
Showed a significantly high value. The femoral fracture stress is
The value increased as the amount of basic protein fraction added increased.
【0047】[0047]
【試験例6】実施例4で得られた乳由来の塩基性タンパ
ク質を配合したプロセスチーズについて、試験例1と同
様の方法で、表12に示す飼料を用い、乳由来の塩基性
タンパク質の添加量とその骨強化作用の関係を検討し
た。乳由来の塩基性タンパク質の量は、配合した飼料中
の乳由来の塩基性タンパク質の量を示すものであるが、
これを飼料中に配合したチーズ100g中の乳由来の塩基性
タンパク質の量に換算すると、A 群は0mg 、B 群は10m
g、C 群は20mg、D 群は50mg、E 群は100mg 、F 群は150
mg となる。Test Example 6 With respect to the processed cheese containing the milk-derived basic protein obtained in Example 4, the feed shown in Table 12 was used in the same manner as in Test Example 1, and the milk-derived basic protein was added. The relationship between the amount and its bone strengthening effect was investigated. The amount of milk-derived basic protein indicates the amount of milk-derived basic protein in the mixed feed,
Converting this to the amount of milk-derived basic protein in 100 g of cheese mixed in the feed, A group was 0 mg and B group was 10 m.
g, C group 20 mg, D group 50 mg, E group 100 mg, F group 150
It becomes mg.
【0048】[0048]
【表12】 [Table 12]
【0049】骨強度の測定は、試験例1と同様に行っ
た。その結果を図6に示す。これによると、大腿骨破断
応力は、対照群(A群) に比べ、乳由来の塩基性タンパク
質を100g当たり50mg以上含有するチーズを飼料に配合し
た群(D、E 、F 群) で統計的に有意に高い値を示した。
また、大腿骨破断応力は、塩基性タンパク質画分の添加
量が増加するに従い高い値を示した。The bone strength was measured in the same manner as in Test Example 1. The result is shown in FIG. According to this, compared with the control group (group A), the femoral fracture stress was statistically higher in the group (D, E, F groups) in which the cheese containing 50 mg or more of the basic protein derived from milk was added to the feed (group D, E, F). Showed a significantly high value.
Further, the femoral fracture stress showed a higher value as the amount of the basic protein fraction added increased.
【0050】[0050]
【比較例1】実施例4で得られた塩基性タンパク質濃縮
物を配合したプロセスチーズについて試験例1と同様の
方法で表13に示す飼料を用い、動物実験により、その
骨強化作用をカルシウム源として炭酸カルシウムまたは
牛骨粉を用いた場合と比較した。尚、表中の()内の数
値は、チーズ由来のものである。[Comparative Example 1] The processed cheese containing the basic protein concentrate obtained in Example 4 was fed with the feeds shown in Table 13 in the same manner as in Test Example 1 and the bone strengthening effect of calcium was determined by animal experiments. It was compared with the case where calcium carbonate or beef bone powder was used as. The values in parentheses in the table are derived from cheese.
【0051】[0051]
【表13】 [Table 13]
【0052】骨強度の測定は試験例1と同様の方法で行
った。その結果を図7に示す。これによると、同量の乳
由来塩基性タンパク質画分と同量のカルシウムを含んで
いても、カルシウム源として炭酸カルシウム(A群) 、牛
骨粉(B群) を加えたものよりチーズ中のカルシウムをカ
ルシウム源として加えたもの(C群) の大腿骨破断応力が
統計的に有意に高い値を示した。The bone strength was measured by the same method as in Test Example 1. FIG. 7 shows the result. According to this, even if it contains the same amount of milk-derived basic protein fraction and the same amount of calcium, calcium in cheese than calcium carbonate (group A) and beef bone meal (group B) added as calcium sources. The rupture stress of the femur of those to which was added as a calcium source (Group C) showed a statistically significantly high value.
【0053】[0053]
【比較例2】 乳由来の塩基性タンパク質画分を含まないヨーグルト
粉末を配合した飼料(A群) 、乳由来の塩基性タンパク
質画分を含まないヨーグルト粉末に乳由来のカルシウム
を強化した飼料(B群) 、乳由来の塩基性タンパク質画
分を含んだヨーグルト粉末を含有する飼料(C群) をそれ
ぞれ調製し、これにより動物実験を行うことで、乳由来
のカルシウムのみを強化した場合と乳由来のカルシウム
と乳由来の塩基性タンパク質画分を強化した場合の骨強
化作用を、表14に示す飼料を用いて、比較実験を行っ
た。尚、表中の()内の数値は、ヨーグルト粉末由来の
ものである。[Comparative Example 2] A feed containing a yogurt powder not containing a milk-derived basic protein fraction (Group A), and a feed containing a milk-derived basic protein fraction-free yogurt powder enriched with milk-derived calcium ( (Group B), a feed containing a yogurt powder containing a milk-derived basic protein fraction (Group C) were prepared respectively, and animal experiments were carried out with these to enhance the milk-derived calcium alone and the milk. A comparative experiment was carried out using the feeds shown in Table 14 for the bone strengthening effect when the calcium-derived and basic protein fractions derived from milk were fortified. The values in parentheses in the table are derived from yogurt powder.
【0054】[0054]
【表14】 [Table 14]
【0055】骨強度の測定は試験例1と同様の方法で行
った。その結果を図8に示す。 A群( コントロール群)
と B群( カルシウム強化群) の比較では、 B群に統計的
な有意差は認められなったが、 A群と C群( 乳由来の塩
基性タンパク質添加群) の比較では C群のラットの大腿
骨破断応力が統計的に有意に大きいという結果を得た。
このことから、骨強化作用は、乳由来のカルシウムと乳
由来の塩基性タンパク質画分を同時に配合した場合に最
も効果があり、乳由来のカルシウムを強化だけでは十分
な骨強化作用が期待できないことが確認された。The bone strength was measured by the same method as in Test Example 1. FIG. 8 shows the result. Group A (control group)
No statistically significant difference was observed between groups B and B (calcium-enhanced group), but a comparison between groups A and C (milk-derived basic protein added group) showed that the rats in group C were The results show that the femoral fracture stress is statistically significant.
From this, the bone strengthening effect is most effective when the milk-derived calcium and the milk-derived basic protein fraction are mixed at the same time, and it is not possible to expect a sufficient bone strengthening effect by strengthening the milk-derived calcium alone. Was confirmed.
【0056】[0056]
【発明の効果】本発明の乳由来の塩基性タンパク質と乳
由来のカルシウムを含有する組成物は、カルシウムの吸
収率を大幅に向上させ、骨強化作用を増強する。また本
発明の骨強化作用を有する組成物は、経口投与製剤また
は飲食品の形態で摂取することができ、乳を原料として
いるために全く副作用がなく、特に飲食品の形態の場合
には、日常の食生活の中で摂取することができるため
に、各種の骨関節疾患、特に骨粗鬆症の予防あるいは治
療に有効である。また、成長期の学童が摂取することに
より、骨強化に有効である。The composition of the present invention containing a milk-derived basic protein and milk-derived calcium significantly improves the absorption rate of calcium and enhances the bone strengthening effect. Further, the composition having a bone-reinforcing effect of the present invention can be ingested in the form of an orally-administered preparation or food and drink, and has no side effects at all because it is made of milk as a raw material, particularly in the case of food and drink, Since it can be taken in daily dietary habits, it is effective in the prevention or treatment of various bone and joint diseases, particularly osteoporosis. It is also effective for bone strengthening when taken by growing school children.
【図1】は、試験例1における、乳由来の塩基性タンパ
クの配合量を変化させた時の骨強度の測定結果を示すグ
ラフである。FIG. 1 is a graph showing the measurement results of bone strength when varying the blending amount of milk-derived basic protein in Test Example 1.
【図2】は、試験例2における、炭酸カルシウムまたは
乳由来のカルシウムの配合量を変化させた時の骨強度の
測定結果を示すグラフである。FIG. 2 is a graph showing the measurement results of bone strength when varying the blending amount of calcium carbonate or milk-derived calcium in Test Example 2.
【図3】は、試験例3における、乳由来の塩基性タンパ
ク質を配合した飲用牛乳の乾燥粉末を飼料に配合した時
の骨強度の測定結果を示すグラフである。FIG. 3 is a graph showing the bone strength measurement results when dry powder of drinking milk containing a milk-derived basic protein was added to the feed in Test Example 3.
【図4】は、試験例4における、一定量の乳由来の塩基
性タンパク質を配合し、更に炭酸カルシウムと乳由来の
カルシウムを同時に配合して、それぞれの量を変化させ
た時の骨強度の測定結果を示すグラフである。FIG. 4 is a graph showing the bone strengths in Test Example 4 in which a fixed amount of basic protein derived from milk was blended, calcium carbonate and calcium derived from milk were blended simultaneously, and the respective amounts were changed. It is a graph which shows a measurement result.
【図5】は、試験例5における、塩基性タンパク質を添
加したヨーグルトを飼料に配合した時の骨強度の測定結
果を示すグラフである。FIG. 5 is a graph showing the measurement results of bone strength when the yogurt containing basic protein was mixed in the feed in Test Example 5.
【図6】は、試験例6における、塩基性タンパク質濃縮
物を添加したプロセスチーズを飼料に配合した時の骨強
度の測定結果を示すグラフである。FIG. 6 is a graph showing the measurement results of bone strength when the processed cheese to which the basic protein concentrate was added was mixed into the feed in Test Example 6.
【図7】は、比較例1における、カルシウム源として炭
酸カルシウム、牛骨粉、プロセスチーズを飼料に配合し
た時の骨強度の測定比較結果を示すグラフである。FIG. 7 is a graph showing the results of measurement and comparison of bone strength when calcium carbonate, beef bone meal, and process cheese were added to the feed as the calcium source in Comparative Example 1.
【図8】は、比較例2における、カルシウム源として、
ヨーグルト粉末およびこれに乳由来のカルシウムを添加
した場合と更に乳由来のカルシウムに乳由来の塩基性タ
ンパク質画分を飼料に添加した場合の骨強度の測定比較
結果を示すグラフである。FIG. 8 shows, as a calcium source in Comparative Example 2,
It is a graph which shows the measurement comparison result of the bone strength when yogurt powder and milk-derived calcium are added thereto and when milk-derived calcium is further added to the diet with a basic protein fraction derived from milk.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A23C 19/00 A23L 1/30 A A61K 38/23 C07K 1/18 8318−4H 14/47 14/65 8318−4H // A61K 35/20 7431−4C (A61K 38/16 ABJ 35:20) (A61K 37/14 ABJ 35:20) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI Technical indication location A23C 19/00 A23L 1/30 A A61K 38/23 C07K 1/18 8318-4H 14/47 14 / 65 8318-4H // A61K 35/20 7431-4C (A61K 38/16 ABJ 35:20) (A61K 37/14 ABJ 35:20)
Claims (10)
来のカルシウムを含有し、骨強化作用を有することを特
徴とする組成物。1. A composition comprising a milk-derived basic protein fraction and milk-derived calcium, and having a bone-reinforcing action.
組成物。2. The composition according to claim 1, which is in the form of a preparation for oral administration.
分を50mg/100g以上、および乳由来のカルシウ
ムを250mg/100g以上含有する請求項1乃至3
のいずれか記載の組成物。5. A milk-derived basic protein fraction of 50 mg / 100 g or more and a milk-derived calcium of 250 mg / 100 g or more are contained on a solid basis.
The composition according to any one of 1.
分を77mg/100g以上、および乳由来のカルシウ
ムを380mg/100g以上含有する請求項4記載の
組成物。6. The composition according to claim 4, which contains 77 mg / 100 g or more of a milk-derived basic protein fraction and 380 mg / 100 g or more of milk-derived calcium in terms of solids.
組成中に塩基性アミノ酸を15重量%以上含有する、請
求項1乃至6のいずれか記載の組成物。7. The composition according to claim 1, wherein the basic protein fraction derived from milk contains 15% by weight or more of basic amino acids in the amino acid composition.
ン様成長因子−1を含有する請求項1乃至7のいずれか
記載の組成物。8. The composition according to claim 1, wherein the milk-derived basic protein fraction contains insulin-like growth factor-1.
ン様成長因子−1を固形換算で200μg/100g以
上含有する請求項8記載の組成物。9. The composition according to claim 8, wherein the milk-derived basic protein fraction contains 200 μg / 100 g or more of insulin-like growth factor-1 in terms of solid.
は乳由来の原料を陽イオン交換樹脂に接触させた後、塩
濃度0.1〜1.0Mの溶液で溶出した画分である、請
求項1乃至9のいずれか記載の組成物。10. A milk-derived basic protein fraction is a fraction obtained by contacting milk or a milk-derived raw material with a cation exchange resin and then eluting with a solution having a salt concentration of 0.1 to 1.0 M. The composition according to any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6333126A JPH08165249A (en) | 1994-12-14 | 1994-12-14 | Composition having bone strengthening action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6333126A JPH08165249A (en) | 1994-12-14 | 1994-12-14 | Composition having bone strengthening action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08165249A true JPH08165249A (en) | 1996-06-25 |
Family
ID=18262589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6333126A Pending JPH08165249A (en) | 1994-12-14 | 1994-12-14 | Composition having bone strengthening action |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08165249A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786473A3 (en) * | 1996-01-23 | 1998-10-07 | Snow Brand Milk Products Co., Ltd. | Basic protein composition, basic peptide composition and application thereof |
| FR2841747A1 (en) * | 2002-07-02 | 2004-01-09 | Cie Laitiere Europeenne | MILK PROTEIN ISOLATE AND PROCESS FOR ITS PREPARATION |
| WO2005016373A1 (en) * | 2003-08-15 | 2005-02-24 | Snow Brand Milk Products Co., Ltd. | Osteogenesis promoter |
| JP2006036690A (en) * | 2004-07-27 | 2006-02-09 | Snow Brand Milk Prod Co Ltd | Osteogenesis promoting agent |
| US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
| EP2392657A1 (en) | 2005-07-05 | 2011-12-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Modified transposon vector and its use |
| WO2014020684A1 (en) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | Cheese and method for producing same |
| US8647619B2 (en) | 2003-08-15 | 2014-02-11 | Megmilk Snow Brand Co., Ltd. | Osteogenesis promoter |
| JPWO2014020678A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
| JPWO2014020680A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| JPWO2014020679A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| JP2017121249A (en) * | 2017-02-28 | 2017-07-13 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
| JP2017123860A (en) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| JP2017123859A (en) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | Fermented milk and method for manufacturing the same |
| CN117859910A (en) * | 2023-12-01 | 2024-04-12 | 君乐宝乳业集团股份有限公司 | Composition for improving osteoporosis and application thereof |
| CN119073589A (en) * | 2024-02-07 | 2024-12-06 | 君乐宝乳业集团股份有限公司 | A composition having the function of promoting bone health and its application |
-
1994
- 1994-12-14 JP JP6333126A patent/JPH08165249A/en active Pending
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976597A (en) * | 1996-01-23 | 1999-11-02 | Fujino Patent Attorney | Basic protein composition, basic peptide composition and application thereof |
| EP0786473A3 (en) * | 1996-01-23 | 1998-10-07 | Snow Brand Milk Products Co., Ltd. | Basic protein composition, basic peptide composition and application thereof |
| US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
| WO2004004482A1 (en) * | 2002-07-02 | 2004-01-15 | Compagnie Laitiere Europeenne | Milk protein isolate and method for preparing same |
| US7247331B2 (en) | 2002-07-02 | 2007-07-24 | Compagnie Laitiere Europeenne | Milk protein isolate and method for preparing same |
| US8603560B2 (en) | 2002-07-02 | 2013-12-10 | Compagnie Laitiere Europeenne | Milk protein isolate and process for its preparation |
| FR2841747A1 (en) * | 2002-07-02 | 2004-01-09 | Cie Laitiere Europeenne | MILK PROTEIN ISOLATE AND PROCESS FOR ITS PREPARATION |
| WO2005016373A1 (en) * | 2003-08-15 | 2005-02-24 | Snow Brand Milk Products Co., Ltd. | Osteogenesis promoter |
| JP2005060321A (en) * | 2003-08-15 | 2005-03-10 | Snow Brand Milk Prod Co Ltd | Osteogenic promotor |
| EP1656948A4 (en) * | 2003-08-15 | 2007-12-26 | Snow Brand Milk Products Co Ltd | Osteogenesis promoter |
| US8647619B2 (en) | 2003-08-15 | 2014-02-11 | Megmilk Snow Brand Co., Ltd. | Osteogenesis promoter |
| JP2006036690A (en) * | 2004-07-27 | 2006-02-09 | Snow Brand Milk Prod Co Ltd | Osteogenesis promoting agent |
| EP2392657A1 (en) | 2005-07-05 | 2011-12-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Modified transposon vector and its use |
| WO2014020684A1 (en) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | Cheese and method for producing same |
| JPWO2014020678A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
| JPWO2014020684A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Cheese and its manufacturing method |
| JPWO2014020680A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| JPWO2014020679A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| US10376543B2 (en) | 2012-07-31 | 2019-08-13 | Megmilk Snow Brand Co., Ltd. | Fermented milk product and method for producing the same |
| US10485853B2 (en) | 2012-07-31 | 2019-11-26 | Megmilk Snow Brand Co., Ltd. | Cheese and method for producing the same |
| US10603362B2 (en) | 2012-07-31 | 2020-03-31 | Megmilk Snow Brand Co., Ltd. | Beverage, and method of producing the same |
| JP2017121249A (en) * | 2017-02-28 | 2017-07-13 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
| JP2017123860A (en) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
| JP2017123859A (en) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | Fermented milk and method for manufacturing the same |
| CN117859910A (en) * | 2023-12-01 | 2024-04-12 | 君乐宝乳业集团股份有限公司 | Composition for improving osteoporosis and application thereof |
| CN119073589A (en) * | 2024-02-07 | 2024-12-06 | 君乐宝乳业集团股份有限公司 | A composition having the function of promoting bone health and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0704218B1 (en) | Bone reinforcing agent and foods and drinks product containing the same | |
| JPH08165249A (en) | Composition having bone strengthening action | |
| WO2019170707A1 (en) | Highly digestible protein-rich nutritional compositions, uses thereof, and methods for preparing the same | |
| WO2005016373A1 (en) | Osteogenesis promoter | |
| TWI586362B (en) | Novel protein material | |
| TWI620506B (en) | Use of yoghurt and method of manufacturing same | |
| TWI620505B (en) | Yoghurt and method of manufacturing same | |
| JPH10290682A (en) | Calcium complex | |
| TWI626010B (en) | Use of milk powder and method of manufacturing same | |
| JPH1156232A (en) | Milk and milk product enriched with vitamin k and calcium | |
| TWI626008B (en) | Use of cheese and method of manufacturing same | |
| EP0915668B1 (en) | Drinkable, acid nutrient composition with long shelf life and health-promoting action | |
| WO2020200984A1 (en) | Nutritional compositions comprising bovine milk proteins, methods for preparing the same and uses thereof | |
| JP2001226289A (en) | Hepatic function ameliorative agent | |
| TW201410160A (en) | Beverage and method of manufacturing same | |
| TWI626007B (en) | Use of cheese and method of manufacturing same | |
| JP6203723B2 (en) | Protein material for bone disease prevention or treatment and method for producing the same | |
| Shchekotova et al. | Development of the calcium-and-collagen-rich soft curd cheese technology | |
| JP6357265B2 (en) | Protein material for bone disease prevention or treatment | |
| JP6357266B2 (en) | Protein material for bone disease prevention or treatment | |
| JP6562957B2 (en) | Fermented milk and method for producing the same | |
| JP6562956B2 (en) | Beverage and method for producing the same | |
| 천정환 et al. | Nutritional functions of milk and dairy products in improving human health | |
| TWI620508B (en) | Beverage and method of manufacturing same | |
| Edition | Lecturer’s Handbook on whey and whey products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050725 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050805 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070313 |